Insights

  • Date

  • Content Type

  • Reset

Blog

Accelerating commercialization of advanced therapies: it’s time to map a new route to market

26.10.21

By Christian Schneider

For decades, advanced therapies have shown potential to disrupt the $1 trillion global pharmaceuticals...

Blog

Biopharma’s Big Inflection Point: There’s never been a better time to innovate with next-generation medicine

11.10.21

By Christian Schneider

In all of the years I have been tracking and helping to drive biotech innovation, I can say...

Blog

How to create a smart integrated drug development plan including considerations for cell and gene therapies

29.06.21

By Dr. Diane Seimetz

An integrated drug development plan is a critical tool for the efficient and effective progression from the R&D...

Blog

Risk Management Plans for ATMPs

13.06.21

By Maria Schacker

ATMPs are a relatively novel class of medicinal products with anew and very unique set of potential risks...

Blog

Neutralizing Antibody Assay Development – a key consideration for immunogenicity packages

1.06.21

By Jennifer Sales

Neutralising Antibodies, or NAbs, are a subclass of Anti-Drug Antibodies that may be formed during an unwanted immunogenic...

Blog

Better late than never? What developers of SARS-CoV-2 vaccines in early-to -late-stage development should consider

12.05.21

By Michael Pfleiderer

Unfortunately, as of today the ongoing pandemic is still far from being under control, with close to 3...